147 results about "Thyreoidin" patented technology

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the invention has the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

The present invention discloses a quantitative detection kit of free thyroxine (fT4) and a method for detecting the free thyroxine with the detection kit. The detection kit comprises a free thyroxine standard, a free thyroxine antigen marked by horseradish peroxidase, an antibody, a magnetic bead separating agent, luminescence substrate reagent and wash liquid. The method for detecting free thyroxine comprises the following steps: adding the free thyroxine standard and sample to be measured into the test tube, adding the free thyroxine antigen marked by horseradish peroxidase and antibody, after mixing to uniform, incubating for one hour in 37 DEG C, then adding magnetic bead separating agent for stewing for 5 minutes, separating for obtaining the immune magnetic microspheres, discarding the supernate, washing the deposit for two times; adding the luminescence substrate reagent, measuring and analyzing the concentration of free thyroxine in sample to be measured. The quantitative detection kit of free thyroxine and the detection method provided by the invention have the advantages of higher stability, higher sensitivity and higher accuracy, and belong to the technical field of immunodiagnosis.

The invention provides a thyrotropin (TSH) chemiluminescent immunoassay quantitative detection kit and a preparation method thereof. The invention has the advantages that the reaction pattern of the double antibody sandwich method is adopted, the chemiluminescent technology combining with the technology of fluorescin isothiocyanate-anti-fluorescein isothiocyanate is effectively utilized, horse radish peroxidase is adopted to be as the marker enzyme to quantitatively detect the content of TSH in the human serum sample, the detection sensitivity is guaranteed, and the raw materials are greatly saved. The kit of the invention has high sensitivity, good repeatability, short reaction time, good stability and long reagent validity, and can provide the experimental basis timely for the clinical diagnosis and the treatment of thyroid disorders.

Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

The present invention provides a compound having the structure:

or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.

The invention relates to a neck skin care product and a preparation technique thereof. The proportioning for the components of neck skin care product is scientific and reasonable; the neck skin care product comprises active ingredients of Limnanthes Alba seed oil (meadowfoam seed oil), palmitoyl pentapeptide, soliquoid of organosilicone elastomers, etc., and the preparation of the neck skin care product aims at caring the neck skin of pregnant women and lying-in women that is characterized by hydropenia and easy aging caused by escalatory secretion of thyrotropin and corticotrophin; the neck skin care product has prominent anti-oxidation and free radical capturing properties, and is not greasy with strong permeability, obviously reinforcing the synthesis of elastin and collagen protein of the skin, smoothening the wrinkles and promoting skin elasticity; meanwhile, the neck skin care product ensures the skin moist and silken texture and covers the fine wrinkles of the neck; through the synergistic effect on the skin from endothecium to surface, the neck skin care product is capable of promoting the elasticity of the skin, preventing the loss of moisture, supplying moisture and nutrition inside the skin simultaneously, and ensuring the skin of the neck to be healthier and more lustrous.

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD- L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.

Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile. The cells may be frozen for storage, and retain their hormone-secretion profile after thawing. The cell cultures are useful for the production of human hormones, for the bio-assay of drugs such as therapeutic gonadotrophin, for the testing of drug efficacy and design, and for toxicity testing of drugs and chemicals. The cells may also be implanted in an individual to replace deficient hormone secretion. For instance, insulin secreting pancreatic cells may be implanted in a diabetic individual as an adjunct or replacement therapy for exogenously administered insulin.

The present invention relates to compounds containing T3 mimetics of phosphonic acid and monoesters, stereoisomers, pharmaceutically acceptable salts, co-crystals thereof, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of prodrugs thereof, and Their preparation and use in the prevention and/or treatment of metabolic diseases such as obesity, nonalcoholic steatohepatitis (NASH), hypercholesterolemia and hyperlipidemia, and related conditions such as atherosclerosis, coronary Cardiac disease, impaired glucose tolerance, metabolic syndrome x, and diabetes uses.

The invention discloses the expressing product of human thyrotropin receptor extracellular domain amino terminus gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-N terminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

The invention provides antibody formulations and methods useful for prophylaxis or treatment of transthyretin-related amyloidosis.

The invention provides methods of detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody binds preferentially to misfolded TTR over native tetrameric form of TTR. The capture antibody binds to an epitope within amino acid residues 89-97 or TTR or to an epitope within amino acid residues 101-109 of TTR. 9D5 and 18C5 are examples of suitable capture antibodies. The methods can be used for diagnosing diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis) and for monitoring the efficacy of TTR therapies, among other applications.

The invention discloses a Parkinson's disease specific serum endogenous small molecule marker and application thereof. The marker contains 2-amino-3-(4-hydroxyl-3-methoxyphenyl) propionic acid, ferulic acid and citraconic acid, altrose, pentadecanoic acid, o-phosphoserine, 4, 6 beta-hydroxymorphine, L-thyroxine, 5[epsilon], 9[epsilon], 16[epsilon]-17-hydroxy peraluminum-19-acid, 8-(1,2,dyhydroxy-3-methylbutyl-3-ene-1-yl)-7-methoxy-2H-chromine-2-2-ketone,10-hydroxydecanoic acid, perfluoro caprylic acid, and Corchorifatty acid F. The Parkinson's disease specific serum endogenous small molecule marker provided by the invention has the characteristics of high accuracy and high sensitivity. The prediction offline prediction area AUC of some markers reaches 0.95 or above, the accuracy and sensitivity of the markers are high, and the markers can be directly used for Parkinson's disease indexes.

The invention discloses application of transthyretin in transferring fusion protein into eyes, belonging to the technical field of protein engineering. The invention provides a method for allowing foreign protein to pass through eye barriers and to be conveyed into eyes through fusion expression of transthyretin as shown in SEQ ID NO.1 and the foreign protein. The results of animal experiments prove that as the fusion protein prepared in the invention is used for eye drop treatment on rats and rabbits, foreign protein can be rapidly and effectively conveyed to fundus. The transthyretin used inthe method is derived from a human body, has good biocompatibility and safety in the human body, and has important application prospects when used as a substitute of injection drugs in the field of medicine.

The invention discloses a micro-fluidic chemiluminescence detecting system for magnetic particles for detecting thyroid functions. The system comprises a bottom plate and an upper chip, and the upperchip comprises a sample adding area in the center of the upper chip and five micro-fluidic reaction detecting channels communicated with the sample adding area, wherein the five micro-fluidic reactiondetecting channels include a total triiodothyronine micro-fluidic reaction detecting channel, a total thyroxine micro-fluidic reaction detecting channel, a free triiodothyronine micro-fluidic reaction detecting channel, a free thyroxine micro-fluidic reaction detecting channel and a thyroid stimulating hormone micro-fluidic reaction detecting channel. In application of the system, the bottom plate is arranged under the upper chip, and magnets which are permanent magnets or electromagnets are arranged at positions, corresponding to magnetic particle coating areas of the micro-fluidic reactiondetecting channels, of the bottom plate. By ingenious combination of the micro-fluidic technology and the magnetic particle chemiluminescence technology, quickness, high sensitivity and accuracy in quantitative detection of target substances are realized.